• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    iRhythm Technologies Announces the Addition of Two Executive Leaders to Advance Strategic Growth and Operational Excellence

    7/25/22 4:15:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email

    SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of two seasoned executives to its leadership team. Brice Bobzien will join the company as the Chief Financial Officer on August 8, 2022, to lead all financial operations of the company as well as to advance the culture of operational excellence and prepare the company for future growth. Reyna Fernandez will join as the company's Executive Vice President, Chief Human Resources Officer on July 25, 2022, to lead the development and implementation of human resources strategies in support of the company's global expansion plans.

    "We are very pleased to welcome Brice and Reyna to our expanded leadership team as we continue to execute upon our vision of building iRhythm into a market leader in the digital healthcare space," said Quentin Blackford, iRhythm's President and CEO. "Brice is a veteran executive who brings a wealth of experience building finance teams and guiding organizations through operational transformations. His focus on operational excellence with a disciplined and rigorous approach to financial management and strategic development will position us well for the future. With the addition of Brice into the CFO role, this will allow Doug to focus on the continued improvement of our operational functions that he will continue to lead. Reyna is a seasoned HR executive with over 25 years of experience in building human resource teams, implementing talent development programs, and transforming organizations to operate strategically, globally and efficiently. We look forward to these two successful individuals joining our team to help lead the organization through significant growth with a focus on operational effectiveness and efficiency."

    About Mr. Bobzien

    Brice Bobzien most recently served as the Senior Vice President, Finance & Investor Relations of Dexcom, Inc., where he was responsible for global financial planning and analysis, investor relations, operations accounting, and global pricing strategy. Brice played an instrumental role in driving revenue growth initiatives that resulted in the company growing from $700 million to forecasted revenues of approximately $2.9 billion for fiscal year 2022. This growth included the scaling of the company's global footprint, expanding beyond the United States and into more than 50 countries. During this time, Brice transformed the finance team into a world class organization designed to foster revenue growth and operational discipline. Brice's track record includes more than 20 years of experience and increasing responsibility at leading medical device companies, including Zimmer Holdings, Inc., NuVasive, Inc. and Dexcom, Inc. Prior to these roles, Brice began his career in public accounting. Brice earned his Bachelor of Science degree in Business Administration from Indiana University, Fort Wayne, and is a Certified Public Accountant (non-practicing) in the state of Indiana.

    About Ms. Fernandez

    Reyna Fernandez most recently served as Chief Human Resources Officer at Intersect ENT, Inc., where she was responsible for envisioning and implementing human resources strategies to support the company in becoming an integrated, world-class player in the therapeutics space. Reyna was instrumental in driving the continued growth of Intersect ENT through best-in-class talent acquisition, organizational effectiveness and human capital management functions. During her tenure with the company, she partnered with the CEO and executive leadership to create a performance culture focused on growth and operational excellence, transformed the HR organization to scale globally in line with business objectives, and worked strategically with the board of directors to align on compensation practices. Reyna brings global experience from her roles with Endologix, Inc., Canon Medical Systems USA, Inc., Johnson & Johnson, and Bristol-Myers Squibb Company. Reyna earned her Master of Social Administration from Columbia University and a Bachelor of Arts degree in Cultural Anthropology from Haverford College in Pennsylvania.

    About iRhythm Technologies, Inc.

    iRhythm is a leading digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change the clinical management of patients.

    Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such statements are based on current assumptions that involve risks and uncertainties, and actual outcomes and results could differ materially from those anticipated. The risks and uncertainties that may cause actual results to differ materially from current expectations, many of which are beyond our control, include risks more fully described in iRhythm's Quarterly Report on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on May 6, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except as required by law, iRhythm assumes no obligation to update any such forward-looking statement after the date of this release.

    Investor Relations Contact

    Stephanie Zhadkevich

    (919) 452-5430

    [email protected]

    iRhythm Media Contact

    Morgan Mathis

    (310) 528-6306

    [email protected]



    Primary Logo

    Get the next $IRTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRTC

    DatePrice TargetRatingAnalyst
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    12/3/2024$86.00Equal Weight
    Wells Fargo
    10/4/2024$78.00Neutral
    Goldman
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    12/11/2023$110.00Neutral → Buy
    Citigroup
    7/19/2023$130.00Outperform
    Robert W. Baird
    2/7/2023$150.00Overweight
    Wells Fargo
    11/7/2022Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $IRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm's Zio LTCM Clinical Superiority

    In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total health care costs.Findings in a younger, commercially insured population build on data from the Medicare fee-for-service, population-based CAMELOT study, confirming the Zio LTCM service's value across patient populations and payer segments. SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced the publication of the real-world evidence study: Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evid

    8/18/25 8:05:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions

    Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a digital health leader focused on creating trusted solutions that detect, predict, and prevent disease, today announced a strategic partnership with Lucem Health, a leader in AI-driven early disease detection, to accelerate early identification of undiagnosed arrhythmias in patient po

    7/31/25 4:10:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces Second Quarter 2025 Financial Results

    SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA Recent Operational Highlights

    7/31/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iRhythm upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00

    5/2/25 8:03:46 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Wells Fargo resumed coverage on iRhythm with a new price target

    Wells Fargo resumed coverage of iRhythm with a rating of Equal Weight and set a new price target of $86.00

    12/3/24 7:33:58 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on iRhythm with a new price target

    Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00

    10/4/24 7:40:56 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    SEC Filings

    View All

    SEC Form 144 filed by iRhythm Technologies Inc.

    144 - iRhythm Technologies, Inc. (0001388658) (Subject)

    8/11/25 4:18:39 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by iRhythm Technologies Inc.

    144 - iRhythm Technologies, Inc. (0001388658) (Subject)

    8/5/25 4:51:34 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by iRhythm Technologies Inc.

    10-Q - iRhythm Technologies, Inc. (0001388658) (Filer)

    7/31/25 5:23:19 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $IRTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Rosenbaum Marc Wade sold $35,918 worth of shares (226 units at $158.93), decreasing direct ownership by 2% to 10,879 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/12/25 4:39:08 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Director Talwalkar Abhijit Y exercised 5,312 shares at a strike of $10.71 and sold $839,381 worth of shares (5,312 units at $158.02) (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/12/25 4:38:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Patterson Chad sold $406,168 worth of shares (2,555 units at $158.97), decreasing direct ownership by 6% to 43,667 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/7/25 4:57:37 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/5/24 11:59:44 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/5/24 5:35:18 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

    4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/6/23 7:08:38 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Leadership Updates

    Live Leadership Updates

    View All

    iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

    iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

    2/29/24 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Derrick Sung Joins Aerin Medical as Chief Financial Officer

    A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

    11/20/23 9:00:00 AM ET
    $IRTC
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

    SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

    6/6/23 9:00:39 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Financials

    Live finance-specific insights

    View All

    iRhythm Technologies Announces Second Quarter 2025 Financial Results

    SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA Recent Operational Highlights

    7/31/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025

    SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading

    7/17/25 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces First Quarter 2025 Financial Results

    SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu

    5/1/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 12:54:21 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 9:52:49 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/7/24 4:05:49 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care